These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1205 related articles for article (PubMed ID: 24960469)

  • 1. Evaluation and medical management of kidney stones in children.
    Tasian GE; Copelovitch L
    J Urol; 2014 Nov; 192(5):1329-36. PubMed ID: 24960469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Functional evaluation in patients with kidney calculi].
    Stojimirović B
    Srp Arh Celok Lek; 1998; 126(9-10):394-8. PubMed ID: 9863414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy.
    Pak CY; Sakhaee K; Fuller CJ
    Trans Assoc Am Physicians; 1983; 96():294-305. PubMed ID: 6679957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.
    Lotan Y; Buendia Jiménez I; Lenoir-Wijnkoop I; Daudon M; Molinier L; Tack I; Nuijten MJ
    BJU Int; 2012 Dec; 110(11 Pt C):E1060-7. PubMed ID: 22686216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and prevention of kidney stones: an update.
    Frassetto L; Kohlstadt I
    Am Fam Physician; 2011 Dec; 84(11):1234-42. PubMed ID: 22150656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of recurrent nephrolithiasis.
    Goldfarb DS; Coe FL
    Am Fam Physician; 1999 Nov; 60(8):2269-76. PubMed ID: 10593318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric urinary stone disease--does age matter?
    Kalorin CM; Zabinski A; Okpareke I; White M; Kogan BA
    J Urol; 2009 May; 181(5):2267-71; discussion 2271. PubMed ID: 19296968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical management of kidney stones: AUA guideline.
    Pearle MS; Goldfarb DS; Assimos DG; Curhan G; Denu-Ciocca CJ; Matlaga BR; Monga M; Penniston KL; Preminger GM; Turk TM; White JR;
    J Urol; 2014 Aug; 192(2):316-24. PubMed ID: 24857648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic abnormalities associated with calyceal diverticular stones.
    Auge BK; Maloney ME; Mathias BJ; Pietrow PK; Preminger GM
    BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical approach to adults.
    Monk RD
    Semin Nephrol; 1996 Sep; 16(5):375-88. PubMed ID: 8890394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of nephrolithiasis: where is the evidence from clinical trials?
    Pachaly MA; Baena CP; Carvalho Md
    J Bras Nefrol; 2016 Mar; 38(1):99-106. PubMed ID: 27049371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
    Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
    J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypocitraturia as a pathogenic risk factor in the mixed (calcium oxalate/uric acid) renal stones.
    Alvarez Arroyo MV; Traba ML; Rapado A
    Urol Int; 1992; 48(3):342-6. PubMed ID: 1589930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study.
    Borghi L; Meschi T; Amato F; Briganti A; Novarini A; Giannini A
    J Urol; 1996 Mar; 155(3):839-43. PubMed ID: 8583588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimum nutrition for kidney stone disease.
    Heilberg IP; Goldfarb DS
    Adv Chronic Kidney Dis; 2013 Mar; 20(2):165-74. PubMed ID: 23439376
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 61.